$Quoin Pharmaceuticals(QNRX.US)$Stock has also fallen over 200% since last Monday is another reason they are ready to cover alomh with the borrow rate increasing from 81% to 315%. When they cover it will reach about 2.71.
$Quoin Pharmaceuticals(QNRX.US)$ ASHBURN, Va., March 05, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced the pricing of its "reasonable best efforts" public offering of 4,062,500 ordinary shares represented by 4,062,500 American Depositary Shares (or pre-funded warrants in lieu thereof), Series D warrants to purchase an aggregate of up to 4,06...
$Quoin Pharmaceuticals(QNRX.US)$looks to be consolidating. I see blocks in the 1.30 range. That's likely where it'll go before it takes off. Then 🚀 to the 🌙!
Quoin Pharmaceuticals Receives FDA Clearance to Recruit Teenagers in Netherton Syndrome Clinical Trials. In a significant development that could potentially alter the trajectory of Netherton Syndrome treatment, Quoin Pharmaceuticals (NASDAQ: QNRX) has received clearance from the U.S. Food and Drug Administration (FDA) to include teenage subjects in their ongoing clinical studies. This decision is expected to broaden the ...
Quoin Pharmaceuticals股票討論區
got to hold a dollar
Watch for shorts to cover shares today or tomorrow before ER
🚨 PUBLIC OFFERING 🚨
ASHBURN, Va., March 05, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced the pricing of its "reasonable best efforts" public offering of 4,062,500 ordinary shares represented by 4,062,500 American Depositary Shares (or pre-funded warrants in lieu thereof), Series D warrants to purchase an aggregate of up to 4,06...
Earnings tomorrow
let's hope that's the catalyst needed to get this back over 4
🚨 WATCHING 🚨
FDA approval and the price tanks
Medical Company Granted FDA Clearance For Netherton Syndrome Clinical Trials
In a significant development that could potentially alter the trajectory of Netherton Syndrome treatment, Quoin Pharmaceuticals (NASDAQ: QNRX) has received clearance from the U.S. Food and Drug Administration (FDA) to include teenage subjects in their ongoing clinical studies. This decision is expected to broaden the ...
back to 5 please
暫無評論